BR112014018278B1 - Vacina e vírus influenza c - Google Patents

Vacina e vírus influenza c Download PDF

Info

Publication number
BR112014018278B1
BR112014018278B1 BR112014018278-7A BR112014018278A BR112014018278B1 BR 112014018278 B1 BR112014018278 B1 BR 112014018278B1 BR 112014018278 A BR112014018278 A BR 112014018278A BR 112014018278 B1 BR112014018278 B1 BR 112014018278B1
Authority
BR
Brazil
Prior art keywords
virus
influenza
vaccine
microliters
pigs
Prior art date
Application number
BR112014018278-7A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014018278A2 (pt
Inventor
Randy R. Simonson
Emily A. Collin
Benjamin M. Hause
Original Assignee
Newport Laboratories, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newport Laboratories, Inc filed Critical Newport Laboratories, Inc
Publication of BR112014018278A2 publication Critical patent/BR112014018278A2/pt
Publication of BR112014018278B1 publication Critical patent/BR112014018278B1/pt

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
BR112014018278-7A 2012-01-27 2013-01-28 Vacina e vírus influenza c BR112014018278B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/385,004 2012-01-27
US13/385,004 US9278999B2 (en) 2012-01-27 2012-01-27 Influenza C virus and vaccine
PCT/US2013/023441 WO2013112995A1 (en) 2012-01-27 2013-01-28 Influenza c virus and vaccine

Publications (2)

Publication Number Publication Date
BR112014018278A2 BR112014018278A2 (pt) 2019-04-02
BR112014018278B1 true BR112014018278B1 (pt) 2023-01-17

Family

ID=47714564

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014018278-7A BR112014018278B1 (pt) 2012-01-27 2013-01-28 Vacina e vírus influenza c

Country Status (13)

Country Link
US (1) US9278999B2 (https=)
EP (1) EP2807184A1 (https=)
JP (1) JP6257529B2 (https=)
CN (1) CN104203972A (https=)
AU (1) AU2013211833B2 (https=)
BR (1) BR112014018278B1 (https=)
CA (1) CA2862328C (https=)
HK (1) HK1201283A1 (https=)
MX (1) MX360831B (https=)
NZ (1) NZ629378A (https=)
PH (1) PH12014501688A1 (https=)
RU (1) RU2656186C2 (https=)
WO (1) WO2013112995A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1209140A1 (en) * 2012-07-19 2016-03-24 Zoetis Services Llc Bovine influenza c virus compositions
AR111770A1 (es) 2017-05-05 2019-08-21 Elanco Us Inc Vacuna para enfermedad respiratoria bovina
CN111363855A (zh) * 2020-04-30 2020-07-03 山东省农业科学院家禽研究所（山东省无特定病原鸡研究中心） 一种同时检测a、d型流感病毒的成套试剂、试剂盒及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004161781A (ja) * 1992-03-03 2004-06-10 Dai Ichi Seiyaku Co Ltd 経口ワクチン
AUPQ846900A0 (en) * 2000-06-29 2000-07-27 Aruba International Pty Ltd A vaccine
JP2010512748A (ja) * 2006-12-15 2010-04-30 シェーリング−プラウ・リミテッド インフルエンザウイルスを培養物中で複製するための方法
TW200927928A (en) 2007-09-24 2009-07-01 Nobilon Internat B V Inactivated influenza vaccine
US20090110698A1 (en) * 2007-10-31 2009-04-30 Newport Laboratories, Inc. Method of determining vaccine compliance
RU2428476C1 (ru) * 2010-06-21 2011-09-10 Учреждение Российской Академии Медицинских Наук Научно-исследовательский институт экспериментальной медицины Северо-западного отделения РАМН (НИИЭМ СЗО РАМН) Реассортантный штамм вируса гриппа rn 1/09-swine a(h7n1) для определения антител к нейраминидазе при гриппозной инфекции и вакцинации

Also Published As

Publication number Publication date
WO2013112995A1 (en) 2013-08-01
JP6257529B2 (ja) 2018-01-10
AU2013211833B2 (en) 2017-09-14
HK1201283A1 (en) 2015-08-28
JP2015506949A (ja) 2015-03-05
MX2014009022A (es) 2015-03-03
CA2862328C (en) 2021-08-31
PH12014501688A1 (en) 2014-10-20
CN104203972A (zh) 2014-12-10
CA2862328A1 (en) 2013-08-01
MX360831B (es) 2018-11-16
AU2013211833A1 (en) 2014-09-18
US20130195915A1 (en) 2013-08-01
RU2656186C2 (ru) 2018-05-31
EP2807184A1 (en) 2014-12-03
NZ629378A (en) 2017-06-30
BR112014018278A2 (pt) 2019-04-02
RU2014134850A (ru) 2016-03-20
US9278999B2 (en) 2016-03-08
AU2013211833A2 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
Polatoğlu et al. COVID‐19 in early 2023: Structure, replication mechanism, variants of SARS‐CoV‐2, diagnostic tests, and vaccine & drug development studies
Fulton et al. Bovine viral diarrhoea virus antigenic diversity: impact on disease and vaccination programmes
Sakamoto et al. Isolation of foot-and-mouth disease virus from Japanese black cattle in Miyazaki Prefecture, Japan, 2000
Khalenkov et al. Detection and isolation of H5N1 influenza virus from large volumes of natural water
BR112014018278B1 (pt) Vacina e vírus influenza c
CN108085301A (zh) 从宿主细胞提取和纯化腺相关病毒和腺病毒的方法及其组分和试剂盒
Zhang et al. Overview of viruses
Biswal et al. Evaluation of FTA® card for the rescue of infectious foot-and-mouth disease virus by chemical transfection of extracted RNA in cultured cells
CN104181297A (zh) 一种检测羊伪狂犬病毒抗体的elisa试剂盒
El-Bagoury et al. Genetic characterization and phylogenetic analysis of Foot and Mouth Disease virus vaccine strains and recent field isolate.
AU2016206243B2 (en) Methods for purification of a virus produced in vitro and clearance assay for the virus
Namroodi et al. Molecular and serological detection of canine distemper virus (CDV) in rural dogs, Iran
Perozo et al. Avian adeno-associated virus-based expression of Newcastle disease virus hemagglutinin-neuraminidase protein for poultry vaccination
Scagliarini et al. Molecular analysis of the NP gene of Italian CDV isolates
Said et al. Efficacy of bivalent inactivated vaccine containing insect cell–expressed avian influenza H5 and egg-based Newcastle disease virus (NDV) against dual infection with highly pathogenic H5N1 and velogenic NDV in chickens
Koekemoer et al. Development of probes for typing African horsesickness virus isolates using a complete set of cloned VP2-genes
CN102827948A (zh) 基于磁性引物扩增的流式细胞术检测食源性病毒的方法及试剂盒
Esnault et al. Optimisation of rapid untargeted nanopore DNA virus metagenomics using cell cultures and calves experimentally infected with bovine herpes virus-1
Speranskaya et al. Genetic diversity and evolution of the influenza C virus
WO2025077807A1 (en) Methods for obtaining high-purity norovirus virus-like particles (vlps)
Maringa Whole genome analysis of rare and/or novel rotavirus strains post-Rotarix® introduction in Zambia
Kaore et al. Laboratory diagnosis of novel H1N1 virus
RU2532843C2 (ru) Способ диагностики гриппа с
Fukumoto et al. The first outbreak of equine coronavirus infection in 13 years among draft horses at Obihiro Racecourse in Japan in 2025
Nishi et al. Potency of two chimeric vaccine candidates derived from the classical swine fever GPE–vaccine strain against a circulating virus strain isolated in Japan

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/01/2013, OBSERVADAS AS CONDICOES LEGAIS